Anti-S100A8 for treating leukemia
The present description relates to an anti-S1008 protein for treating leukemia. More specifically, is disclosed anti-S100A8 antibody that specifically binds to a portion of S100A8 protein and/or a S100A8/S100A9 heterodimer for treating leukemia.
1. An anti-S100A8 antibody, wherein said anti-S100A8 antibody comprises a heavy chain variable region encoded by the nucleotide sequence set forth in SEQ ID NO: 3 or a heavy chain variable region consisting of SEQ ID NO: 4, and said anti-S100A8 antibody comprises a light chain variable region encoded by the nucleotide sequence set forth in SEQ ID NO: 5 or a light chain variable region consisting of SEQ ID NO: 6.
2. The anti-S100A8 antibody of claim 1 , wherein said anti-S100A8 specifically binds to a S100A8/S100A8 homodimer or a S100A8/S100A9 heterodimer.
3. The anti-S100A8 antibody of claim 2 , wherein the anti-S100A8 specifically binds to S100A8 protein is a human S100A8.
4. The anti-S100A8 antibody of claim 3 , wherein the human S100A8 comprises the amino acid sequence depicted in SEQ ID NO: 1.
5. The anti-S100A8 antibody of claim 1 , wherein said anti-S100A8 is monoclonal or polyclonal antibody.
6. The anti-S100A8 antibody of claim 1 , wherein said anti-S100A8 is a mouse antibody, a goat antibody, a human antibody or a rabbit antibody.
7. The anti-S100A8 antibody of claim 1 , wherein said anti-S100A8 is a humanized antibody.
8. The anti-S100A8 antibody claim 1 , formulated for an administration with a chemotherapeutic agent.
9. The anti-S100A8 antibody of claim 8 , wherein the chemotherapeutic agent is at least one of daunorubicin, doxorubicin and cytarabine.
10. A composition comprising the anti-S100A8 antibody claim 1 and a carrier.
11. The composition of claim 10 , further comprising a S100A9 peptide or a peptidomimetic thereof.
12. The composition of claim 11 , wherein the S100A9 peptide is human S100A9 protein.
13. A method of treating leukemia, stimulating cell differentiation, and/or for inhibiting cell proliferation in a subject comprising the step of administering the anti-S100A8 antibody claim 1 to said subject.
14. The method of claim 13 , wherein said leukemia is acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML) and chronic myelomonocytic leukemia (CMML).